Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment

Απλή σελίδα τεκμηρίου
dc.contributor.authorElefsiniotis, I. S.en
dc.contributor.authorPetrocheilou, A.en
dc.contributor.authorScarmeas, N.en
dc.contributor.authorKetikoglou, I.en
dc.contributor.authorPantazis, K. D.en
dc.contributor.authorToutouza, M.en
dc.contributor.authorTsianos, E. V.en
dc.date.accessioned2015-11-24T18:52:03Z
dc.date.available2015-11-24T18:52:03Z
dc.identifier.issn1386-6532-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18347
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAntiviral Agents/therapeutic useen
dc.subjectCalcitonin/*blooden
dc.subjectDrug Therapy, Combinationen
dc.subjectFemaleen
dc.subjectHepatitis C, Chronic/drug therapy/*metabolismen
dc.subjectHumansen
dc.subjectInterferon-alpha/*pharmacology/therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPolyethylene Glycols/*pharmacology/therapeutic useen
dc.subjectProtein Precursors/*blooden
dc.subjectRecombinant Proteinsen
dc.subjectRibavirin/*pharmacology/therapeutic useen
dc.titleSerum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatmenten
heal.abstractOBJECTIVES: To evaluate the alterations of serum procalcitonin (PCT) levels in patients with chronic hepatitis C during pegylated interferon-alpha (PEG-IFNa) plus ribavirin (RIB) treatment and to correlate them with clinical and virological outcomes. STUDY DESIGN: Fifty-two consecutive patients (29 males, age=41.2+/-14.7 years) with chronic HCV-related liver disease (six cirrhotics) were evaluated for PCT levels at baseline and during the treatment course (at week 12, 24, 48 and 72) with PEG-IFNa plus RIB. Sustained virological response (SVR) was confirmed by undetectable serum HCV-RNA at the end of treatment and again 6 months after completion of treatment. RESULTS: Two patients exhibited culture-proved bacterial infections during the treatment course. Thirty-six patients (69.2%) exhibit SVR and 16 (30.8%) were non-responders. Serum PCT levels remained within normal limits (0.1-0.5 ng/mL) in all treated patients throughout the follow-up period except those two who exhibited bacterial infections during the treatment course. Virological responders exhibited significant decline of serum PCT levels over time compared to non-responders (p<0.001), even when adjusted for multiple baseline parameters (p=0.037). CONCLUSION: Serum PCT levels decline in chronic hepatitis C patients during PEG-IFNa plus RIB treatment, especially in the sustained virological responder group, while they elevate only when bacterial infections complicate the treatment course.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1016/j.jcv.2006.08.014-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16996792-
heal.identifier.secondaryhttp://ac.els-cdn.com/S138665320600309X/1-s2.0-S138665320600309X-main.pdf?_tid=dc7d584a5da888c1736411ebe3a7ef4e&acdnat=1333694946_3623b094efbd29a46999653767383feb-
heal.journalNameJ Clin Virolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2006-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ